CNBC - Healthcare

The bigger issue at hand may be that many Americans fall into a large, uncertain middle ground – neither firmly pro-vaccine nor staunchly opposed.

BioMarin will acquire Alesta Therapeutics for $275 million upfront, bolstering BioMarin's unit focused on rare skeletal conditions.

The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.

Hims & Hers CEO Andrew Dudum spoke to CNBC about the FTC's lawsuit against the company, compounded GLP-1 drugs and AI.

Nome uses AI and drug-development expertise to help rare disease families turn genetic diagnoses into potential paths toward treatment.